0
0
London, UK – A new study published in the Archives of Disease in Childhood has cast doubt on the long-term effects of puberty blockers and hormone therapy on children and adolescents experiencing gender dysphoria.
The research, conducted by Canadian scientists, pooled data from existing studies to assess the impact of these treatments. The findings, which echo concerns raised by the UK’s Hilary Cass review, indicate a significant lack of conclusive evidence regarding the benefits and potential risks associated with these interventions.
Puberty blockers aim to delay the onset of puberty, while hormone therapy seeks to induce secondary sex characteristics aligned with the individual’s gender identity.
The study analyzed data from multiple sources, including observational studies and before-and-after comparisons. The researchers found very low certainty evidence regarding the impact of puberty blockers on overall health, well-being, and depression. Similarly, for hormone therapy, the evidence was deemed insufficient to confidently determine its effects on mental and physical health, including the risk of serious side effects like cardiovascular issues.
“There remains considerable uncertainty regarding the effects of puberty blockers and gender-affirming hormone therapy,” the researchers conclude. “Methodologically rigorous prospective studies are needed to produce higher certainty evidence.”
This research highlights the urgent need for further investigation into the long-term consequences of these treatments. Critics argue that the lack of solid evidence necessitates a more cautious approach to gender-affirming care for minors.
Disclaimer: This article is for informational purposes only and does not constitute medical advice.
Note: This article provides a concise summary of the research findings. For a more detailed understanding, refer to the original study published in the Archives of Disease in Childhood.
